Fedora Pharmaceuticals Inc. is dedicated to the discovery and development of novel antibiotics targeting life-threatening microbial drug resistance. Fedora's management and scientific team of staff and collaborators bring a wealth of knowledge and expertise in drug discovery and development as demonstrated by the extensive lists of drugs both in development and in clinical use developed by Fedora's team.
Fedora's pipeline includes the first ever β-Lactamase inhibitors with potent activity against highly resistant bacterial strains including the newly emerging metallo-β-lactamase NDM-1. Fedora is currently advancing these new leads through late stage pre-clinical development and hope to begin human clinical trials by the first quarter of 2014.
"Innovative Approaches for Improved Health"